BR112023003807A2 - Derivado de amina - Google Patents

Derivado de amina

Info

Publication number
BR112023003807A2
BR112023003807A2 BR112023003807A BR112023003807A BR112023003807A2 BR 112023003807 A2 BR112023003807 A2 BR 112023003807A2 BR 112023003807 A BR112023003807 A BR 112023003807A BR 112023003807 A BR112023003807 A BR 112023003807A BR 112023003807 A2 BR112023003807 A2 BR 112023003807A2
Authority
BR
Brazil
Prior art keywords
amine derivative
dyrk
represented
formula
pharmaceutically acceptable
Prior art date
Application number
BR112023003807A
Other languages
English (en)
Portuguese (pt)
Inventor
Tojo Shingo
Urabe Daisuke
Watanabe Hitoshi
Kawahata Wataru
Moriyama Hideki
Asamitsu Yuko
Original Assignee
Sumitomo Pharma Co Ltd
Carna Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Pharma Co Ltd, Carna Biosciences Inc filed Critical Sumitomo Pharma Co Ltd
Publication of BR112023003807A2 publication Critical patent/BR112023003807A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112023003807A 2020-09-18 2021-09-17 Derivado de amina BR112023003807A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020157398 2020-09-18
JP2021122893 2021-07-28
PCT/JP2021/034327 WO2022059779A1 (ja) 2020-09-18 2021-09-17 アミン誘導体

Publications (1)

Publication Number Publication Date
BR112023003807A2 true BR112023003807A2 (pt) 2023-03-28

Family

ID=80776131

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023003807A BR112023003807A2 (pt) 2020-09-18 2021-09-17 Derivado de amina

Country Status (10)

Country Link
US (1) US20230365589A1 (https=)
EP (1) EP4215534A4 (https=)
JP (2) JP7706775B2 (https=)
KR (1) KR20230069162A (https=)
CN (1) CN116209441A (https=)
AU (1) AU2021343770A1 (https=)
BR (1) BR112023003807A2 (https=)
CA (1) CA3191617A1 (https=)
MX (1) MX2023003245A (https=)
WO (1) WO2022059779A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023008470A1 (ja) * 2021-07-28 2023-02-02 住友ファーマ株式会社 縮環アミン誘導体
WO2025170029A1 (ja) * 2024-02-09 2025-08-14 カルナバイオサイエンス株式会社 ジヒドロキナゾリノン誘導体

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020084116A (ko) * 2000-02-07 2002-11-04 애보트 게엠베하 운트 콤파니 카게 2-벤조티아졸릴 우레아 유도체 및 이의 단백질 키나제억제제로서의 용도
EP1679308B1 (en) 2003-10-15 2013-07-24 Ube Industries, Ltd. Novel indazole derivative
WO2008021338A2 (en) * 2006-08-15 2008-02-21 Wyeth Tricyclic oxazolidone derivatives useful as pr modulators
JP2010163361A (ja) 2007-04-27 2010-07-29 Dainippon Sumitomo Pharma Co Ltd キノリン誘導体
KR20100010894A (ko) 2008-07-23 2010-02-02 가부시키가이샤 키노파마 Dyrk를 저해하는 화합물을 함유하는 의약 조성물
US8470835B2 (en) 2009-01-13 2013-06-25 Glaxo Group Limited Pyrimidinecarboxamide derivatives as inhibitors of Syk kinase
TW201039825A (en) 2009-02-20 2010-11-16 Astrazeneca Ab Cyclopropyl amide derivatives 983
CN102712601A (zh) * 2009-11-12 2012-10-03 赛尔维他股份公司 化合物、其制备方法、药物组合物、化合物的用途、用于调节或调控丝氨酸/苏氨酸激酶的方法以及丝氨酸/苏氨酸激酶调节剂
CA2816219C (en) 2010-11-01 2019-10-29 Portola Pharmaceuticals, Inc. Nicotinamides as syk modulators
UY34200A (es) 2011-07-21 2013-02-28 Bayer Ip Gmbh 3-(fluorovinil)pirazoles y su uso
US9446044B2 (en) 2011-08-19 2016-09-20 Diaxonhit DYRK1 inhibitors and uses thereof
WO2013043002A1 (en) 2011-09-23 2013-03-28 Yuhan Corporation Imide-containing benzothiazole derivative or its salt and pharmaceutical composition comprising the same
KR101916443B1 (ko) 2012-07-26 2018-11-08 글락소 그룹 리미티드 Pad4 억제제로서의 2-(아자인돌-2-일) 벤즈이미다졸
RS63405B1 (sr) 2013-10-25 2022-08-31 Blueprint Medicines Corp Inhibitori receptora faktora rasta fibroblasta
JP2015107945A (ja) 2013-12-05 2015-06-11 国立大学法人京都大学 神経新生に関する化合物及び医薬組成物
GB201401886D0 (en) * 2014-02-04 2014-03-19 Lytix Biopharma As Neurodegenerative therapies
JP2017516850A (ja) 2014-05-23 2017-06-22 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Jak阻害剤である5−クロロ−2−ジフルオロメトキシフェニルピラゾロピリミジン化合物
WO2016044641A2 (en) 2014-09-17 2016-03-24 Epizyme, Inc. Carm1 inhibitors and uses thereof
GB201617339D0 (en) 2016-10-12 2016-11-23 Lytix Biopharma As Therapeutic compounds
CN109206537B (zh) 2018-10-10 2021-04-09 华熙生物科技股份有限公司 一种乙酰化透明质酸钠的制备方法及其应用
US20230138851A1 (en) * 2020-01-30 2023-05-04 Carna Biosciences, Inc. Novel alkyne derivatives

Also Published As

Publication number Publication date
AU2021343770A9 (en) 2024-09-12
KR20230069162A (ko) 2023-05-18
MX2023003245A (es) 2023-04-11
JP2025134941A (ja) 2025-09-17
JP7706775B2 (ja) 2025-07-14
EP4215534A1 (en) 2023-07-26
US20230365589A1 (en) 2023-11-16
EP4215534A4 (en) 2024-10-02
CA3191617A1 (en) 2022-03-24
CN116209441A (zh) 2023-06-02
JPWO2022059779A1 (https=) 2022-03-24
TW202227459A (zh) 2022-07-16
AU2021343770A1 (en) 2023-05-18
WO2022059779A1 (ja) 2022-03-24

Similar Documents

Publication Publication Date Title
CO2023017082A2 (es) Compuestos de tiadiazolilo unidos a un átomo de oxígeno como inhibidores de dna polimerasa θ
JOP20190115B1 (ar) مثبّطات إنزيم بولي (adp-ريبوز) بوليمراز (parp)
BR112014001018A2 (pt) derivado de azabenzimidazol tendo atividade de ativação de ampk
BR112022025613A2 (pt) Novo inibidor de secreção de ácido e uso do mesmo
BRPI0818193B8 (pt) composto, composição farmacêutica, e, uso de um composto
BR112022000598A2 (pt) Composto de ureia para antagonização de receptor de lpa1
BR112012013049A2 (pt) potencializador do efeito antitumor.
BR112015009777A2 (pt) derivado de amina ou sal do mesmo
BR112013020996A8 (pt) derivados aminobutíricos substituídos como inibidores de neprilisina
BR112013010310A2 (pt) inibidores de acetil-coa carboxilase de lactama n1/n2
BR112023015359A2 (pt) Composto de pirimidopirano
BR112012007090A2 (pt) inibidor da atividade da heparanase
BR112012027373A2 (pt) composição pesticida e seu uso
BR112015019790A2 (pt) derivado de piridina monocíclica
MX391414B (es) Compuesto novedoso de bifenilo o sal del mismo.
TW201613904A (en) Pyridone derivatives containing tetrahydropyranylmethyl group
BR112013017974A2 (pt) inibidores de pirimidina girase e topoisomerase iv
BR112015029348A2 (pt) inibidores da bace
BR112016011016A8 (pt) derivados de fenoxietila de amina cíclica, seus usos, e composição farmacêutica.
MX368178B (es) Compuestos de ácido dimetilbenzoico.
BR112023026538A2 (pt) Pirazóis com pirimidinil substituído como inibidores de cdk2
BR112023003807A2 (pt) Derivado de amina
BR112017008794A2 (pt) inibidores de di-heteroaril histona desacetilase e seu uso em terapia
BR112015028760A2 (pt) compostos para inibição de cepas de integrase do hiv-1 resistentes a drogas
NZ746906A (en) Oxaborole esters and uses thereof

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]